logo

CNRT Raises $14 Million; Will Develop BTG’s TheraSphere® in China

CNRT
Published on: Jul 19, 2019
Author: Amy Liu

Chengdu New Radiomedicine Technology(CNRT) raised $14 million in a funding round led by BTG Asia, a subsidiary of London healthcare investor BTG plc. BTG, which contributed $11 million to the round, said it will collaborate with CNRT to develop its TheraSphere® nuclear cancer treatment in China. CNRT provides medical isotopes for tumor diagnosis and treatment. In 2013, BRT paid $200 million to acquire the TheraSphere technology, which is approved to treat hepatocellular carcinoma in many countries. Earlier this year, CNRT completed Phase I construction of its pilot plant.

Source: China Biotoday

Suggested Opportunity

Dynacor Group Inc.

Dynacor Group Inc. (TSX: DNG)

Dynacor Group Inc. is a gold production corporation headquartered in Montreal, Canada. The corporation is engaged in production through its government licensed ore processing operations. At present, Dynacor produces and explores in Peru where its management team has decades of experience and expertise.

Biotechnology Genomics Life Science Pharmaceutical

Related Posts